Novartis mulling $1.5 million-$5 million price range for gene therapy Zolgensma
U.S. regulators are due to make a decision on approving Novartis' Zolgensma next month.
ZURICH: Novartis Chief Executive Vas Narasimhan said on Wednesday that the Swiss drugmaker is examining a price range for its Zolgensma gene therapy for spinal muscular atrophy(SMA) of between $1.5 million and $5 million per patient.
"At a $500,000 per QALY cut-off, the medicine is cost-effective in the range of $4-$5 million, and at a $150,000 per QALY cutoff, it's cost-effective at a range of $1.5 million," Narasimhan told analysts on a call, using the acronym for quality-adjusted life year used to help assess a treatment's value.
"That's the range that we're looking at. That hopefully gives you some of the boundaries," he added.
U.S. regulators are due to make a decision on approving Zolgensma next month.
Medical Dialogues had earlier reported that Novartis had filed for U.S. Food and Drug Administration (USFDA)approval of the gene therapy, Zolgensma, and a decision was expected within weeks. The FDA submission was based on findings from a trial of 15 babies treated with Zolgensma.
Read Also: Second death in Novartis gene therapy trials under investigation
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd